SCHEMBL4417836

SCHEMBL4417836

C1OCOC(OC2OCOCO2)O1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8174388 0.79 TSHR (0.33) TSHR
SCHEMBL7174181 0.73
SCHEMBL4872362 0.67
SCHEMBL4868123 0.66 TSHR (0.36) TSHR
SCHEMBL6506279 0.66
SCHEMBL456363 0.65 TSHR (0.42) TSHR
SCHEMBL9130280 0.60
SCHEMBL9442550 0.59
SCHEMBL1789455 0.59
SCHEMBL22493081 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3714328-A1 METHOD FOR PRODUCING A PLANAR POLYMERIC STACK Arkema France (FR) 2020-09-30 EP disclosed
EP-1461340-B1 TRIOXANE DERIVATIVES AS ANTIMALARIA OR ANTICANCER COMPOUNDS UFC LTD (GB) 2009-04-08 EP disclosed
US-20050070595-A1 Trioxane derivatives as antimalaria or anticancer compounds UFC LIMITED (GB) 2005-03-31 US disclosed
EP-1461340-A2 TRIOXANE DERIVATIVES AS ANTIMALARIA OR ANTICANCER COMPOUNDS UFC LIMITED (GB) 2004-09-29 EP disclosed
WO-2003048168-A2 TRIOXANE DERIVATIVES AS ANTIMALARIA OR ANTICANCER COMPOUNDS UFC LIMITED (GB) 2003-06-12 WO disclosed
US-RE38117-E1 Trioxane dimer compound having antiproliferative and antitumor activities HAUSER, INC. 2003-05-06 US disclosed
EP-1021438-A4 TRIOXANE DIMER COMPOUNDS HAVING ANTIPROLIFERATIVE AND ANTITUMOR ACTIVITIES HAUSER INC (US) 2002-08-28 EP disclosed
EP-1021438-A1 TRIOXANE DIMER COMPOUNDS HAVING ANTIPROLIFERATIVE AND ANTITUMOR ACTIVITIES Hauser, Inc. (US) 2000-07-26 EP disclosed
US-6004997-A ANTICANCER AGENTS HAUSER, INC. (US) 1999-12-21 US disclosed
US-5840925-A Trioxane dimer compounds having antiproliferative and antitumor activities HAUSER, INC. (US) 1998-11-24 US disclosed
WO-1998024786-A9 TRIOXANE DIMER COMPOUNDS HAVING ANTIPROLIFERATIVE AND ANTITUMOR ACTIVITIES 1998-10-08 WO disclosed
WO-1998024786-A1 TRIOXANE DIMER COMPOUNDS HAVING ANTIPROLIFERATIVE AND ANTITUMOR ACTIVITIES HAUSER, INC. (US) 1998-06-11 WO disclosed
WO-1993014756-A1 1,2,4-TRIOXANE COMPOUNDS HAVING ANTIMALARIAL ACTIVITY THE JOHNS HOPKINS UNIVERSITY (US) 1993-08-05 WO disclosed
US-5225437-A 1,2,4-trioxane compounds having antimalarial activity THE JOHNS HOPKINS UNIVERSITY (US) 1993-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070595-A1 Trioxane derivatives as antimalaria or anticancer compounds PHOSPHO1, PIK3CA, PFKFB1 TSHR 2993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.